用于监测非肌层浸润性膀胱癌（NMIBC）的尿液生物标记物的临床实施：欧洲泌尿学协会非肌浸润性膀胱癌指南小组的考虑因素。

IF 8.3 1区医学 Q1 ONCOLOGY European urology oncology Pub Date : 2024-09-28 DOI:10.1016/j.euo.2024.09.011

Fredrik Liedberg, Paramananthan Mariappan, Paolo Gontero

{"title":"用于监测非肌层浸润性膀胱癌（NMIBC）的尿液生物标记物的临床实施：欧洲泌尿学协会非肌浸润性膀胱癌指南小组的考虑因素。","authors":"Fredrik Liedberg, Paramananthan Mariappan, Paolo Gontero","doi":"10.1016/j.euo.2024.09.011","DOIUrl":null,"url":null,"abstract":"Although high-level evidence is currently lacking, noninferiority randomised controlled trials in predefined risk groups in non-muscle-invasive bladder cancer are under way to scientifically prove the safety of urinary biomarker-guided follow-up. To facilitate recommendations for clinical use, it is essential to comply with the EU certification for in vitro diagnostics and to demonstrate cost effectiveness.","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3000,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical Implementation of Urinary Biomarkers for Surveillance of Non-muscle-invasive Bladder Cancer (NMIBC): Considerations from the European Association of Urology NMIBC Guideline Panel.\",\"authors\":\"Fredrik Liedberg, Paramananthan Mariappan, Paolo Gontero\",\"doi\":\"10.1016/j.euo.2024.09.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Although high-level evidence is currently lacking, noninferiority randomised controlled trials in predefined risk groups in non-muscle-invasive bladder cancer are under way to scientifically prove the safety of urinary biomarker-guided follow-up. To facilitate recommendations for clinical use, it is essential to comply with the EU certification for in vitro diagnostics and to demonstrate cost effectiveness.\",\"PeriodicalId\":12256,\"journal\":{\"name\":\"European urology oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":8.3000,\"publicationDate\":\"2024-09-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European urology oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.euo.2024.09.011\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euo.2024.09.011","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

虽然目前还缺乏高水平的证据，但正在对非肌层浸润性膀胱癌的预定风险组进行非劣效性随机对照试验，以科学地证明尿液生物标志物指导随访的安全性。为了便于推荐临床使用，必须符合欧盟的体外诊断认证并证明其成本效益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Clinical Implementation of Urinary Biomarkers for Surveillance of Non-muscle-invasive Bladder Cancer (NMIBC): Considerations from the European Association of Urology NMIBC Guideline Panel.

Although high-level evidence is currently lacking, noninferiority randomised controlled trials in predefined risk groups in non-muscle-invasive bladder cancer are under way to scientifically prove the safety of urinary biomarker-guided follow-up. To facilitate recommendations for clinical use, it is essential to comply with the EU certification for in vitro diagnostics and to demonstrate cost effectiveness.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European urology oncology Multiple-

CiteScore

15.50

自引率

2.40%

发文量

128

审稿时长

20 days

期刊介绍： Journal Name: European Urology Oncology Affiliation: Official Journal of the European Association of Urology Focus: First official publication of the EAU fully devoted to the study of genitourinary malignancies Aims to deliver high-quality research Content: Includes original articles, opinion piece editorials, and invited reviews Covers clinical, basic, and translational research Publication Frequency: Six times a year in electronic format